This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Organovo Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Organovo.
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
by Zacks Equity Research
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E for outsized gains.
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Organovo (ONVO) Stock
by Zacks Equity Research
Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.
Organovo (ONVO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 14.29% and -10.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Organovo (ONVO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Organovo (ONVO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organovo (ONVO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -40.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
Can The Uptrend Continue for Organovo Holdings (ONVO)?
by Zacks Equity Research
Investors certainly have to be happy with Organovo Holdings, Inc. (ONVO) and its short term performance
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
Try Rising P/E Investing With 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
by Zacks Equity Research
Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
Take the Less-Trodden Path: Rising P/E for 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek